InMed Forms Strategic Collaboration to Develop PhytoCannabinoid Therapies
2015-03-10 – News Release – InMed Pharmaceuticals Inc. (IN:CSE) has formed an exclusive strategic collaboration with the University of Debrecen, Hungary, to develop novel phytocannabinoid-based therapies to treat ocular allergic symptoms. The collaboration will leverage InMed’s proprietary intelligent cannabinoid drug design platform (IDP) and will be led by one of the world’s leading cannabinoid researchers, Dr. Tamas Biro, MD, PhD, DSc. Dr. Biro has extensive research experience in studying the endocannabinoid system (ECS) and the closely related transient receptor potential (TRP) channels in various human diseases.
Under the discovery and development collaboration InMed’s IDP platform will be used to identify cannabinoid-based and non-cannabinoid-based phytochemicals for ocular therapies focused on reducing various pro-inflammatory cytokines in in vitro and in vivo models.
Dr. Sazzad Hossain, chief scientific officer of InMed, stated: “We have accumulated significant experience and expertise in developing cannabinoids to treat ocular disease, which forms the basis of this strategic collaboration. As we prepare to initiate phase 1 clinical trials of our lead phytocannabinoid-based drug candidate CTI-085 for glaucoma, we look forward to expanding our ophthalmic therapy pipeline by developing ocular anti-allergic drugs, where we expect Dr. Biro’s 18 years of experience in this specialty field to be invaluable.”
“The global ocular allergy space is a multibillion-dollar market, and our platform offers a novel approach to potentially treating a wide array of allergies,” said Craig Schneider, president and chief executive officer of InMed. “We are excited to move a lead candidate toward preclinical and clinical trials and will provide additional updates as they become available.”
We seek Safe Harbor.
- Published in Blog, Life Sciences, Medical Marijuana
Nomad Ventures (NMD:V) receives Sand and Gravel Permit for it’s St. Vincent Bay Property
2015-03-09 – News Release – Nomad Ventures Inc. (NMD:TSXV) has received its sand and gravel permit for the St. Vincent Bay quarry, located on the Sunshine Coast of British Columbia. This permit is granted by the BC Ministry of Energy and Mines and indicates the Provincial Government’s approval of Nomad’s Work System and Reclamation Plan as prepared and submitted by the Company on April 23, 2014.
The permit entitles the Company to commence operations on the property as a commercial sand, gravel and granite quarry.
A reclamation bond has been posted by the Company and has been accepted by the Ministry of Energy and Mines as part of this approval process.
The Sand and Gravel Permit allows the Company to begin production operations at the quarry. Nomad Ventures will begin by clearing and stripping the mine footprint (raw material source area) in preparation for sand, gravel and quarried stone extraction and processing. The Company is very pleased with the successful accomplishment of this significant milestone and looks forward to beginning work on the property as soon as equipment and crews can be mobilized.
Delivery of aggregate product to customers will begin as soon as the site is prepared and the mandated official notifications are made to local communities and the Ministry of Energy and Mines.
The commencement of production on the St. Vincent Bay Property will not be based on a feasibility study of mineral reserves demonstrating economic and technical viability and therefore there is increased uncertainty and risk of failure associated with this production decision. Production will be subject to the Company obtaining sales contracts for the purchase of sand, gravel and/or quarried stone product. The Company is actively pursuing sales contracts for its products.
James H. Place, P.Geo., a Director of the company and a Qualified Person as defined in NI43-101, has reviewed and approved the scientific and technical content of this news release.
We seek Safe Harbor.
Greece: Living on a Prayer
By: Frehiwote Negash –
In light of the European Central Banks’s refusal to loan more money to Greek banks to stave off financial ruin, Greece’s newly elected Prime Minister Alexis Tsipras stated that Europe has “a noose tied to Greek necks”. Since 2010, Greece’s massive debt crises has snowballed and has put the European Union in a precarious financial situation as they struggle to decide whether the country is worth saving at the expense of all EU members. Greece narrowly avoided disaster last month at the 11th hour when Euro zone finance ministers decided to extend their loan by another 4 months in an effort to avoid the credit crunch and allow Greece the time to reorganize. With the European Central Banks’s announcement today, the Greek government is facing an uphill battle as the country is cash strapped and is quickly running out of time. The central issue here is that Greece has so much debt to banks in the Eurozone, particularly Germany that it has to keep refinancing that debt. Greece has repaid the first 310 million euro installment of a loan from the International Monetary Fund while it struggles to cover its domestic funding necessities. Greece must pay a total of 1.5 billion euros to the International Monetary Fund in March, with the subsequent payments due on March 13, 16 and 20.
Tsipras had asked the European Central Bank for a bridge loan to ride out the country’s immediate funding issues, while it renegotiates the terms of the country’s second bailout in 5 years. However, the rest of the Eurozone was against a new loan deal unless Greece pledges to continue austerity measures. This is a daunting task for the newly formed leftist government which got elected in January on a promise to fix Greece’s economic issues by ending austerity and to renegotiate Greece’s 240 billion-euro; a promise that is going to be a challenge for them to keep in light of the ECB’s refusal to loan more money to the country. Germany, Greece’s largest creditor has made it clear that in order for the country to continue receiving financial assistance, austerity measures must be a part of the Greek government’s plans. These measures include cuts in pensions and minimum wage and significant cuts in the private and public sector making it difficult for the Greek government to keep its promise if the country wants to avoid financial ruin. Austerity is a nonnegotiable condition for Greece’s creditors and it will be the focal point in the next round of Eurozone discussions. Greece has to demonstrate that it is sincere in its efforts to right its economic ship and come up with a viable plan that not only meets the demands of their creditors but is a plan that . Unfortunately for Tsipras, that means breaking a lot of election promises.
Sources: The Telegraph, Reuters, National Post
- Published in Blog
InMed Pharmaceuticals to Present Live Investor Webcast March 5
Company invites individual and institutional investors as well as advisors to attend interactive real-time presentation at VirtualInvestorConferences.com
Craig Schneider, Chief Executive Officer, will provide a company overview during a live webcast at VirtualInvestorConferences.com.
DATE: Thursday, March 5, 2014
TIME: 1:15pm ET
LINK: http://VirtualInvestorConferences.com > click the red “register/ watch event now” button
This will be a live, interactive online event where investors are invited to ask the company questions in real-time – both in the presentation hall as well as InMed’s “virtual trade booth.” If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.
It is recommended that investors pre-register to save time and receive event updates.
About InMed
InMed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company. For more information, visit www.inmedpharma.com.
About VirtualInvestorConferences.com
Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PR Newswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire’s leading-edge online conferencing and investor communications capabilities with BetterInvesting’s extensive retail investor audience network.
- Published in Blog
Sirona’s Partner Completes SBM-TFC-039 Toxicology Test
Positive Preclinical Toxicology Results for its SGLT2 Inhibitor Trigger Milestone Payment from Wanbang Biopharmaceuticals
Sirona Biochem Corp. (TSX VENTURE: SBM) today announced that Wanbang Biopharmaceuticals has successfully completed the toxicology study in the pre-clinical validation of its anti-diabetic SGLT2 Inhibitor, SBM-TFC-039, for the treatment of Type 2 diabetes.
In the study, SBM-TFC-039 was orally administered to Sprague Dawley (SD) rats for 14 days to evaluate safety and simultaneously observe toxicokinetics. Dosing of SBM-TFC-039 was either 0, 100, 300 or 800 milligrams per kilogram per day (mg/kg/day) as well as 300 mg/kg/day of the reference drug Canagliflozin.
The results of the study demonstrated that the maximum tolerated dose (MTD) of SBM-TFC-039 was greater than 800 mg/kg/day, which was significantly greater than the 300 mg/kg/day of the Canagliflozin reference. There was no mortality in the groups treated with SBM-TFC-039 and the histopathology showed no visual abnormalities.
The reference drug Canagliflozin is Johnson and Johnson’s SGLT2 inhibitor for type 2 diabetes. It was the first SGLT2 inhibitor launched and it has been on the market in many countries including the United States since 2013. Sales in 2013 were $150 million and in 2014 were $622 million. Sales forecasts for this year are $1 billion.
The completion of this test will trigger a milestone payment to Sirona from Wanbang Biopharmaceuticals as part of the $9.5M in upfront and milestone payments.
“The results of the toxicology study are very encouraging. They provide the preclinical validation to proceed to second line testing which comprises of additional safety and tolerability testing with pharmacokinetics. This is the last step required before moving towards investigational new drug (IND) status in humans”, said Attila Hajdu, Chief Business Development Officer of Sirona Biochem.
About Wanbang Biopharmaceuticals
Wanbang Biopharmaceuticals is the leading pharmaceutical company in China that specializes in research, production and marketing of medicines for diabetes, cardiovascular disease and endocrinology. Among domestic pharmaceutical companies, Wanbang Biopharmaceuticals is one of the largest manufacturers and marketers of a comprehensive portfolio of drugs for diabetes. Wanbang Biopharmaceuticals is a subsidiary of Shanghai Pharmaceutical Group which is listed on the Shanghai Stock Exchange. Fosun Pharma, one of the major shareholders of Sinopharm Group, the largest drug distributor in China, is part of Fosun International, the leading non-state owned enterprise group in China which is listed on the Hong Kong Stock Exchange.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential. Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information please visit www.sironabiochem.com
- Published in Blog, Life Sciences
InMed Pharmaceuticals on the Rise
By Frehiwote Negash –
As the marijuana debate continues to dominate headlines on both sides of the border, there are emerging players that have taken the pharmaceutical approach by developing therapeutic options using cannabinoids and testing their effectiveness via clinical trials. As marijuana gains traction as a viable medical option, it is not surprising to see the pharmaceutical companies like Otsuka, Novartis, Eli Lilly and GW Pharma all getting involved in therapy development using cannabinoids in what could be a lucrative opportunity.
In light of changing public perception, Vancouver based InMed Pharmaceuticals (C: IN, OTCQB: IMLFF) formally known as Cannabis Technologies has been on a tear in recent weeks with their share price nearly tripling. After reaching a low of $0.11 in December, the company has rebranded and teamed up with Tiberend Strategic Advisors to increase their exposure to the American market, particularly in the biotech world and is creating buzz. The price was bolstered by their recent showing at the J.P Morgan Biotech show in January and their latest announcement of a new therapy for Epidermolysis bullosa simplex; a genetic skin condition that makes the epidermis fragile and causes it to blister. This foray into developing dermatological therapies makes sense if you consider that there are no FDA approved drugs on the market for this condition. This is the third therapy in the companies’ roster of treatments with therapies for glaucoma and arthritic joint pain already in the pipeline.
While the development of new cannabinoid-based therapies is vital to the company’s fortunes, what distinguishes InMed from their competition is their unique proprietary platform technology. The platform is designed to accelerate the process in which drugs go through the requisite clinical trials and receive government approval for public consumption. Instead of the standard 10-15 year wait for FDA approval, the platform allows for development and commercialization within 3-5 years. If time is of the utmost importance, then InMed has struck gold with this platform.
Investor interest is high and for good reason. With world renowned Dr. Sazzad Hossien, Ph.D., as their Chief Scientific Officer and the recent additions of Dr. Tarek Mansour, Ph.D., a veteran in the pharmaceutical sector, and Kevin Puil, a reputable investment manager on the Board of Directors, InMed has a brilliant management team with extensive knowledge in the pharmaceutical industry and the knowhow to capitalize on a growing market. InMed will be holding an Interactive Investor Webcast on March 5th at 1:15 PM EST. This is a golden opportunity for investors to look at a company with tons of potential and a promising future.
Source: InMed Pharmaceuticals , CNN Money
- Published in Blog, Life Sciences, Medical Marijuana
InMed Pharmaceuticals (IN:CSE) Appoints Dr. Abo Mohammed as Chief Medical Officer
Inmed Pharmaceuticals announced today that it has appointed former Associate Medical Director of GW Pharmaceuticals, Abo Mohammed –
VANCOUVER, British Columbia, March 4, 2015 /PRNewswire/ — InMed Pharmaceuticals, Inc. (“InMed”) (CSE: IN; OTCQB: IMLFF), a clinical stage biopharmaceutical company specializing in the development of cannabinoid based therapies, today announced that it has appointed former Associate Medical Director of GW Pharmaceuticals, Abo Mohammed, MD, DPM, MFPM, as Chief Medical Officer, effective immediately. Dr. Mohammed is a proven leader in the development of cannabinoid therapies, having played a strategic role in the clinical development, R&D, and commercialization of these specialty drugs.
As Chief Medical Officer, Dr. Mohammed will join InMed’s executive management team and will be directly involved in developing the clinical trial strategy for InMed’s lead candidates and product development strategy for the Company’s pipeline of cannabinoid based therapies, including its two clinical stage programs, CTI-085 and CTI-091, and the recently initiated program for Epidermolysis bullosa simplex (EBS), INM-750.
“Our recent progress and anticipated advancement of our lead drug candidates have made the creation of the Chief Medical Officer position a corporate priority,” commented Craig Schneider, Chief Executive Officer of InMed Pharmaceuticals. “There are very few individuals world-wide who have Dr. Mohammed’s level of expertise and direct experience in cannabinoid drug development. We are very fortunate to have been able to attract such a qualified executive to the InMed team.”
Dr. Sazzad Hossain, Chief Scientific Officer, added, “Dr. Mohammed’s expertise in regulatory affairs, clinical development and marketing in the cannabinoid based therapies is expected to add immediate value to InMed as we seek to successfully advance our cannabinoid based therapies along the clinical and regulatory pathway.”
Dr. Mohammed commented, “Joining InMed at this transformative stage, as the company prepares for clinical development of its lead programs, is the opportunity I’d been seeking to continue my passion for bringing cannabinoid therapies to the market. I look forward to leveraging my expertise in support of InMed’s exciting drug candidates.”
Prior to joining InMed Pharmaceuticals, Dr. Mohammed served as Associate Medical Director at GW Pharmaceuticals; a UK-based Pharmaceutical Company specializing in the development of cannabinoid based prescription medicines. In this role, and others at GW Pharmaceuticals, Dr. Mohammed was involved in the advanced delivery of core clinical research and was involved in key decision-making regarding R&D and product commercialization. He played a leading role in GW Pharmaceuticals’ pharmacovigilance team where his responsibilities included handling of the company’s drug safety data from both clinical trials and post-marketing sources, and general management of safety signals including investigations, reviews and reporting. He is also a consultant to the Nigerian regulatory authority (NAFDAC) in the areas of pharmacovigilance, post-marketing surveillance and clinical trials.
Prior to joining GW Pharmaceuticals Dr. Mohammed was with PPD, a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Dr. Mohammed also served as Chief Medical Officer/Clinical Director in various public healthcare establishments in Africa from 1996 to November 2010.
Dr. Mohammed received his MD at Ahmadu Bello University, Zaria Nigeria followed by an MSc in Orthopaedics at University College London. Dr. Mohammed achieved a DipPharMed in Pharmaceutical Medicine at University of Wales in Cardiff. He is Member, Faculty of Pharmaceutical Medicine (Royal College of Physicians of England), the British Association of Pharmaceutical Physicians and the International Society for Pharmacovigilance.
About InMed
InMed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company.
For more information, visit www.inmedpharma.com
- Published in Blog, Life Sciences, Medical Marijuana
- 1
- 2